-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Buy on Dianthus Therapeutics, Maintains $40 Price Target

Benzinga·05/13/2025 10:56:34
Listen to the news
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Dianthus Therapeutics (NASDAQ:DNTH) with a Buy and maintains $40 price target.